Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cluster of Differentiation 27 (CD27)
- Target
- CD27
- Molecular classification
- Tumor necrosis factor receptor (TNFR) superfamily, Type I transmembrane glycoprotein
01
Overview
CD27 is a type I transmembrane glycoprotein belonging to the TNF receptor superfamily. It is expressed on various immune cells, including T cells, NK cells, and B cells, and plays a crucial role as a co-stimulatory immune checkpoint molecule. CD27 interacts with its ligand CD70 to regulate T cell immunity, B cell activation, and immunoglobulin synthesis. Engagement with CD70 triggers signaling cascades that activate NF-kB and MAPK pathways, leading to immune cell activation, proliferation, and survival. Due to its role in promoting anti-tumor immunity, CD27 is being targeted for cancer immunotherapy, with anti-CD27 drugs currently under clinical investigation. Soluble CD27 (sCD27) can be detected in serum/urine and shows potential as a biomarker.
02
Mechanism of action
Co-stimulatory immune checkpoint blockade
03
Biological functions
Immune responseCo-stimulationT cell activationB cell activationRegulation of immunoglobulin synthesisDifferentiation of cytotoxic T lymphocytes (CTLs)Clonal expansionSurvivalMemory formation of cytotoxic T lymphocytes (CTLs)NK cell activityCytokine productionNF-kB pathway activationMAPK8/JNK pathway activation
04
Disease associations
CancerAutoimmunityViral infections
05
Safety considerations
Potential autoimmunity/tolerance breakdownTumor evasion mechanisms
06
Interacting drugs
Anti-CD27 drugs (under clinical investigation)
07
Biomarkers
Soluble CD27 (sCD27)
Beyond the preview
Go deeper on Cluster of Differentiation 27 (CD27).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cluster of Differentiation 27 (CD27).